1 |
Jamalhanjani M, Wilson GA, Mcgranahan N, et al. Tracking the Evolution of Non-Small-Cell Lung Cancer.[J]. N Engl J Med, 2017, 376(22): 2109-2121.
|
2 |
Wang S, Cang S, Liu D. Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer.[J]. J Hematol Oncol, 2016, 9(1): 34.
|
3 |
Denicola GM, Chen PH, Mullarky E, et al. Erratum: NRF2 regulates serine biosynthesis in non-small cell lung cancer[J]. Nature Genetics, 2016, 48(4): 473.
|
4 |
Karoubi G, Gugger M, Schmid R, et al. OCT4 expression in human non-small cell lung cancer: implications for therapeutic intervention.[J]. Interact Cardiovasc Thorac Surg, 2009, 8(4): 393-397.
|
5 |
Soria J C, Ohe Y, Vansteenkiste J, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.[J]. New Engl J Med, 2018, 378(2): 113.
|
6 |
Sodja E, Rijavec M, Koren A, et al. The prognostic value of whole bloodSOX2,NANOGandOCT4mRNA expression in advanced small-cell lung cancer[J]. Radiology & Oncology, 2016, 50(2): 188-196.
|
7 |
Kobayashi I, Takahashi F, Nurwidya F, et al. Oct4 plays a crucial role in the maintenance of gefitinib-resistant lung cancer stem cells[J]. Biochem Biophys Res Commun, 2016, 473(1): 125-132.
|
8 |
何圆. 非小细胞肺癌免疫治疗进展[J]. 中国肺癌杂志,2014, 36(3): 277-281.
|
9 |
Wang L, Chen Z, An L, et al. Analysis of Long Non-Coding RNA Expression Profiles in Non-Small Cell Lung Cancer[J]. Cellul Phys Biochem, 2016, 38(6): 2389-2400.
|
10 |
David Pérez-Callejo, Romero A, Provencio M, et al. Liquid biopsy based biomarkers in non-small cell lung cancer for diagnosis and treatment monitoring[J]. Transl Lung Cancer Res, 2016, 5(5): 455-465.
|
11 |
Zhou J, Zhao C, Zhao J, et al. Re-biopsy and liquid biopsy for patients with non-small cell lung cancer after EGFR-tyrosine kinase inhibitor failure[J]. Thorac Cancer, 2019, 10(4): 957-965.
|
12 |
解淑萍,王雪艳,魏玉菊,等. 非小细胞肺癌的CT表现及其诊断价值[J]. 中国组织工程研究,2016, (A02): 188-189.
|
13 |
樊黎明,胡志东. LncRNA在非小细胞肺癌中的研究进展[J]. 中国肺癌杂志,2016, 19(2): 108-112.
|
14 |
丁碧莎,孙月娟,王海燕. DC-CIK联合化疗治疗非小细胞肺癌的研究进展[J]. 中国免疫学杂志,2016, 32(6): 916-919.
|
15 |
郭卫东. 探析DC-CIK联合化疗治疗晚期非小细胞肺癌的临床效果[J]. 中华肿瘤防治杂志,2016, 23(5): 335-336.
|
16 |
张连美,仲纪祥,孙苏安. EGFR、ALK和Ki-67在非小细胞肺癌中的表达及相关性分析[J]. 临床肺科杂志,2017, 22(1): 4-7.
|
17 |
王春梅,高艳丽,尹丽霞. 非小细胞肺癌放射治疗研究进展[J]. 中华肿瘤防治杂志,2017, 24(10): 720-724.
|
18 |
杜军华,乔洪源,尹宜发. 血清CEA、CA125及Cyfra21-1水平对中晚期非小细胞肺癌患者预后的影响[J]. 肿瘤防治研究,2016, 43(2): 137-140.
|
19 |
张浩业,邹志田,裴艳志,等. Ⅰ期非小细胞肺癌GRP94和淋巴结微转移与预后相关性分析[J]. 中华肿瘤防治杂志,2017, 24(9): 602-605.
|
20 |
彭东旭,方晓娟,杜均详,等. 培美曲塞联合顺铂化疗对晚期非小细胞肺癌患者血清肿瘤标志物的影响[J]. 临床肺科杂志,2016, 21(7): 1306-1309.
|
21 |
徐婕,戴凯琴,凌霜,等. 非小细胞肺癌及其肿瘤干细胞中TGF-β/Smad信号通路及中药干预研究进展[J]. 中成药,2018(6).
|
22 |
Li W, Wang Z, Zha L, et al. HMGA2 regulates epithelial-mesenchymal transition and the acquisition of tumor stem cell properties through TWIST1 in gastric cancer.[J]. Oncology Reports, 2017, 37(1): 185-192.
|
23 |
Phan LC, Trinh NV, Pham PV. Low concentrations of 5-aza-2′-deoxycytidine induce breast cancer stem cell differentiation by triggering tumor suppressor gene expression[J]. Oncotargets & Therapy, 2016, 9: 49-59.
|
24 |
俞岚,焦云杰,周蕾,等. 上皮性卵巢癌中八聚体结合转录因子4、Notch1及DLL4的表达及其临床意义[J]. 南方医科大学学报,2017, 37(4): 444-450.
|
25 |
张敏,虞正鑫,景发,等. 八聚体结合转录因子4与磷酸化蛋白激酶B在结直肠癌中的表达及其临床意义[J]. 肿瘤研究与临床,2018(5).
|
26 |
田玲,吴桂新,余慧青. 非小细胞肺癌组织中Oct4的表达及其与临床病理参数的关系[J]. 国际检验医学杂志,2018(11).
|
27 |
Kalthur G, Salian S R, Nair R, et al. Distribution pattern of cytoplasmic organelles, spindle integrity, oxidative stress, octamer-binding transcription factor 4 (Oct4) expression and developmental potential of oocytes following multiple superovulation[J]. Reproduction Fertility & Development, 2016, 28(12).
|
28 |
于洋,王春仙,索勇. 干细胞标记物OCT4在膀胱癌中的表达及其临床意义[J]. 解放军医药杂志,2016, 28(8): 19-22.
|
29 |
Li B, Yao Z, Wan Y, et al. Overexpression of OCT4 is associated with gefitinib resistance in non-small cell lung cancer:[J]. Oncotarget, 2016, 7(47): 77342-77347.
|
30 |
Li L, Lv Y, Zhang Y, et al. Expression and clinical significance of Oct-4 and E-cad in non-small-cell lung cancer[J]. Oncology Letters, 2016, 11(1): 234.
|